alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › glucagon-like-peptide

glucagon-like-peptide

3 studies tagged glucagon-like-peptide, dated 2021-03-19 to 2023-09-13. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies 2023-09-13
  2. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer's and Parkinson's diseases 2022-07-27
  3. Brain insulin, insulin-like growth factor 1 and glucagon-like peptide 1 signalling in Alzheimer's disease 2021-03-19

Studies

3 studies carry this tag.

Date range

2021 to 2023

Top journals

  • Frontiers in pharmacology 1
  • Frontiers in synaptic neuroscience 1
  • Journal of neuroendocrinology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. Frontiers in pharmacology 2023-09-13 Drug development

    Alzheimer's disease (AD) is a degenerative disease of the nervous system.

  2. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer's and Parkinson's diseases

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in synaptic neuroscience 2022-07-27 Drug development

    Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are peptide hormones and growth factors.

  3. Brain insulin, insulin-like growth factor 1 and glucagon-like peptide 1 signalling in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of neuroendocrinology 2021-03-19 Drug development

    Although the brain was once considered an insulin-independent organ, insulin signalling is now recognised as being central to neuronal health and to the function of synapses and brain circuits.

All topic tags with their study counts